key: cord-0841379-ktmwpj6v
authors: Yetmar, Zachary A; Chesdachai, Supavit; Kashour, Tarek; Riaz, Muhammad; Gerberi, Danielle J; Badley, Andrew D; Berbari, Elie F; Tleyjeh, Imad M
title: Prior Statins Use and Risk of Mortality and Severe Disease from COVID-19: A Systematic Review and Meta-Analysis
date: 2021-05-28
journal: Open Forum Infect Dis
DOI: 10.1093/ofid/ofab284
sha: 40803fcd2714cfcd5ffb98aaef02db4c738cf8ce
doc_id: 841379
cord_uid: ktmwpj6v

BACKGROUND: Statins up-regulate angiotensin converting enzyme-2, the receptor of SARS-CoV-2, while also exhibiting pleiotropic antiviral, antithrombotic and anti-inflammatory properties. Uncertainties exist about their effect on the course of SARS-CoV-2 infection. OBJECTIVES: We sought to systematically review the literature and perform a meta-analysis to examine the association between prior statins use and outcomes of patients with COVID-19. METHODS: We searched Ovid MEDLINE, Web of Science, Scopus, and the preprint server MedRxiv from inception to December 2020. We assessed the quality of eligible studies with the Newcastle-Ottawa quality scale. We pooled adjusted risk ratios (aRR) of the association between prior statins use and outcomes of patients with COVID-19 using the DerSimonian-Laird random effects model and assessed heterogeneity using the I (2)-index. RESULTS: Overall, 19 (16 cohorts and 3 case-control) studies were eligible, with a total of 395,513 patients. Sixteen of 19 studies had low- or moderate-risk of bias. Among 109,080 patients enrolled in 13 separate studies, prior statins use was associated with a lower risk of mortality, (pooled aRR 0.65 (95% CI 0.56-0.77, I (2) = 84.1%) and a reduced risk of severe COVID-19 was also observed in 48,110 patients enrolled in 9 studies, (pooled aRR of 0.73 (95% CI 0.57-0.94, I (2) = 82.8%), with no evidence of publication bias. CONCLUSIONS: Cumulative evidence suggests that prior statins use is associated with lower risks of mortality or severe disease in patients with COVID-19. These data support the continued use of statins medications in patients with an indication for lipid-lowering therapy during the COVID-19 pandemic.

A c c e p t e d M a n u s c r i p t 3

Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), the viral agent responsible for Coronavirus Disease-2019 (COVID- 19) , was identified in December 2019 and quickly spread globally. As of February 8, 2021, over 113 million people have been infected resulting in 2.5 million deaths [1] . Due to the scope of this pandemic, assessment of predictors associated with increased morbidity and mortality of COVID-19 are warranted.

There is an ongoing controversy on the impact of statins, a commonly used class of lipidlowering medications working through inhibition of 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase, on patients with COVID-19. Statins are known to possess pleiotropic characteristics such as anti-inflammatory and immunomodulatory properties. They have been shown to reduce tolllike receptor (TLR) expression and cytokine levels and modulate T-cell responses [2] [3] [4] . Furthermore, COVID-19 has been associated with significant thromboembolic complications and statins have been posited to have antithrombotic effects [5, 6] .

In spite of these beneficial properties, statins are thought to up-regulate expression of angiotensin converting enzyme-2 (ACE2) receptor, the target for SARS-CoV-2 [7] [8] [9] . This may theoretically increase the risk of SARS-CoV-2 infectivity. However, ACE2 has been shown to be protective against acute lung injury (ALI) in the murine sepsis and acid aspiration model [10] . This observation along with the documented protective effects of statins against ALI may indicate that the net effect of statins in COVID-19 disease may be favorable [11] [12] [13] [14] [15] [16] .

It is also well established that patients with underlying cardiovascular diseases are at higher risk for developing severe COVID-19 and death [17, 18] . Furthermore, COVID-19 disease is associated with a higher incidence of cardiovascular complications, where statins could play an important preventive role [19] .

A c c e p t e d M a n u s c r i p t 4 Statins have been previously evaluated in other infectious and inflammatory syndromes. A meta-analysis of observational studies of prevention or treatment of infections showed that prior statins use is associated with a lower risk of infections and mortality [20] . Other meta-analyses of statins in community-acquired pneumonia, influenza, and sepsis showed similar associations with statins [21] [22] [23] [24] . However, a meta-analysis of randomized controlled trials of de novo use of statins in sepsis and a randomized controlled trial for simvastatin in acute respiratory distress syndrome (ARDS) did not show an impact on mortality or progression to severe sepsis [25, 26] . Therefore, we sought to systematically review the literature and perform a meta-analysis to examine the association between prior statins use and outcomes of patients with COVID-19.

A comprehensive systematic review and meta-analysis was conducted according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) [27] and Meta-Analysis of Observational Studies in Epidemiology guidelines [28] . This study was registered in the International Prospective Register of Systematic Reviews (PROSPERO, registration number CRD42021227604).

Studies reporting an association between prior use of statins medications and outcomes of patients with COVID-19 were eligible for inclusion. Examined outcomes included mortality, severe COVID-19, hospitalization, and diagnosis of COVID-19. Two reviewers (Z.A.Y. and S.C.) independently examined eligible studies. Unresolved disagreements after discussion were addressed by a third reviewer (I.M.T.).

A c c e p t e d M a n u s c r i p t 5 The literature was searched by an experienced medical librarian (D.J.G.) for the concepts of COVID-19 and statin medications. Search strategies were created using a combination of keywords and standardized index terms. Searches were run in December 2020 in Ovid EBM Reviews, Ovid Embase (1974+), Ovid Medline (1946+ including epub ahead of print, in-process and other nonindexed citations), Scopus (1970+), and Web of Science Core Collection (1975+). Search results were limited to English language articles. All results were exported to Endnote where duplicates were removed, leaving 427 citations. Search strategies are provided in the supplementary materials. We also queried medRxiv, the preprint server for health sciences, for non-peer reviewed articles that were not captured by the preceding search strategy.

Data on study population demographics, comorbidities, statin exposure, and outcomes was extracted by two reviewers (Z.A.Y. and S.C.) independently. This was subsequently reviewed by the senior reviewer (I.M.T.). Mortality outcomes included in-hospital mortality, 28-day mortality, and 30day mortality. We defined severe COVID-19 as any of the following: requirement of advanced ventilator support, intensive care unit (ICU) admission, or ARDS, either alone or as a composite with mortality. In the event where studies were missing required data for our analyses, we made inquiries to respective corresponding authors.

Eligible studies were assessed by the Newcastle-Ottawa quality assessment scale (NOS) [29, 30] . The NOS rates observational studies based on three parameters: selection, comparability between exposed and unexposed groups, and exposure and outcome assessment. These three domains can have a maximum score of four, two, and three stars, respectively. Studies with less than five stars are considered low quality, five to seven stars moderate quality, and more than seven stars are high quality. Studies deemed at high-risk of bias (low quality studies) were excluded from quantitative analysis. Two reviewers (Z.A.Y. and S.C.) assessed quality of included studies with NOS.

A c c e p t e d M a n u s c r i p t 6 Statistical Analysis

We extracted data on the effect estimates in the form of adjusted odds ratios (ORs), relative risks (RRs) and hazards ratios (HRs). Before conducting the meta-analysis and pooling the effect estimates, we converted adjusted ORs to RRs, if appropriate information was available [31] . To pool the effect estimates, we used the DerSimonian-Laird random effects model [32] with the inverse variance weighting method (and constructed corresponding Forest plots) that recognizes studies as a sample of all potential studies and incorporates a between-study random effect component to allow for between study heterogeneity [33] . If the effect estimates from both multivariable and propensity-matched analyses were available, we included the estimates from the multivariable analyses.

Heterogeneity among included studies was assessed using the I 2 -index [34] . To explore sources of heterogeneity, we conducted univariable meta-regressions to assess the impact of different variables on the overall estimate of effect. Our regression covariates were chosen a priori and consisted of study level variables (when available): mean/median age, sex, proportion of patients with coronary artery disease, diabetes mellitus, smokers, hypertension, dyslipidemia, lung disease, stroke, peripheral vascular disease, malignancy, statins dose intensity, and preprint vs.

published studies.

We constructed contour-enhanced funnel plots [35] and performed an Egger precisionweighted linear regression test as a statistical test of funnel plot asymmetry and publication bias [36] . By identifying the regions of the funnel plot that correspond to statistically significant effects, an assessment can be made as to whether the location of the perceived missing studies is in significant or non-significant regions. All analyses were conducted using Stata statistical software (StataCorp 2011, release 12, College Station, Texas). A c c e p t e d M a n u s c r i p t 7 The results of our literature search are presented in Figure 1 . Nineteen studies met a priorioutlined eligibility criteria with a total of 395,513 patients (table 1) [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] . All studies were observational, including 16 retrospective cohort studies and 3 case-control studies ( Table 2 remaining study was considered at risk of bias due to inadequate adjustment for confounding [54] .

One study of 37,212 patients found that prior rosuvastatin use was associated with a lower risk of COVID-19 infection after extensive matching based on age, gender, body mass index (BMI), smoking, socioeconomic status, and multiple comorbidities, with OR of 0.746 (95% CI 0.645-0.858) [45].

However, another study of 49,245 patients showed that prior statins use was associated with an increased risk of acquiring COVID-19 with an OR of 2.50 (95% CI 1.48-4.21), after adjusting for age, gender, and BMI [54] . The third study of 235,928 patients included two statistical models which first accounted for age, gender, ethnicity, and deprivation index, followed by additional adjustment for smoking, alcohol use, adiposity, blood pressure, spirometry, and physical capability. Though the first model showed a statistically significant increased risk of COVID-19, this lost significance in the second model [44] . Due to limited data, quantitative analysis of the association between statin use and the risk of developing COVID-19 disease could not be performed.

Our systematic review and meta-analysis suggests that prior statins use was associated with reduced mortality and lower risk of severe disease among COVID-19 patients. The pooled effect estimates of several studies at low-to moderate-risk of bias, which enrolled large number of 

These findings might be explained by several mechanisms including immune modulation, anti-inflammatory effects, and anti-thrombotic properties. Statins have been demonstrated to reduce endothelial cell injury involved in thromboembolism formation, which may influence outcomes by reducing thromboembolic complications [56] . Statins have also been shown to reduce expression of TLR and cytokines, which are important mediators in host antiviral response [57] .

Statins also inhibit T-cell activation and proliferation, further modulating the immune response [4] . It is theorized that these mechanisms may contribute to reduced inflammation and improved outcomes in those taking statins.

Statins have been shown to reduce ALI in different animals' models through reduction in TLRs, cytokine expression, inflammatory cell infiltration, vascular permeability and others [11] [12] [13] [14] [15] .

Similar anti-inflammatory effects have been demonstrated in a human experiment of lipopolysaccharide inhalation in healthy volunteers [16] . In a clinical trial of ARDS, statin therapy was associated with better outcomes in the subset of patients with hyperinflammatory phenotype [58] .

Severe COVID-19 disease is associated with a similar hyperinflammatory response and hence, statin therapy may reduce disease severity by similar mechanisms.

Patients with COVID-19 are also at high risk for cardiac complications, with as many as 23% of hospitalized patients with COVID-19 experiencing a major adverse cardiovascular event [19] . A large body of evidence indicates that statins improve cardiovascular outcomes through lipid A c c e p t e d M a n u s c r i p t 10 lowering and non-lipid lowering effects [59, 60] . Prior studies have also shown improved outcomes in patients taking indicated drug therapy for hypertension [61] and diabetes mellitus [62] . Hence, the observed reduced mortality with statins in COVID-19 could be explained at least in part through their favorable effects on the cardiovascular system. Furthermore, statins use has previously been identified as a marker for undergoing other health maintenance measures, such as disease screening and vaccinations, which could account for some of the effect seen in COVID-19.

We did not identify enough studies to pool the effect of statins on acquiring COVID-19.

Studies included for qualitative analysis reported conflicting findings with variable risk of bias. Prior studies have revealed an association between statin use and lower odds of cardiovascular implantable electronic device infections [64] and nosocomial infection following stroke [65] . While the theorized mechanisms in these studies relied on anti-inflammatory and anti-bacterial properties, statins have a more complex relationship with SARS-CoV-2 due to its up-regulation of the virus's target receptor, ACE2. This could theoretically increase the likelihood of acquiring SARS-CoV-2 among exposed individuals. However, ACE2 expression and cell membrane ACE2 density is not the major factor that determines SARS-CoV and SARS-CoV-2 cell entry [66] . A similar concern regarding increased ACE2 expression has also been raised with angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs). However, recent studies indicate that ACEI and ARB therapy is actually associated with better survival in patients with COVID-19 disease [67] .

Additionally, ACEIs and ARBs were not associated with increased risk of acquiring SARS-CoV-2 infection [68] . However, the effect statins may have on acquiring SARS-CoV-2 is unclear.

Although we observed that statin therapy was associated with better outcomes among A c c e p t e d M a n u s c r i p t 28 

A practical treatment for patients with ebola virus disease

Are statins safe in patients with COVID-19?

Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: A comprehensive review

Venous Thromboembolism in COVID-19 ICU Patients

A randomized trial of rosuvastatin in the prevention of venous thromboembolism

COVID-19, ACE2, and the cardiovascular consequences

Tissue specific up regulation of ACE2 in rabbit model of atherosclerosis by atorvastatin: Role of epigenetic histone modifications

Potential role of statins in COVID-19

Angiotensin-converting enzyme 2 protects from severe acute lung

A role for hydroxy-methylglutaryl coenzyme A reductase in pulmonary inflammation and host defense

Effect of pravastatin on bleomycin-induced acute lung injury and pulmonary fibrosis

Pretreatment with atorvastatin attenuates lung injury caused by high-stretch mechanical ventilation in an isolated rabbit lung model

Adrenomedullin attenuates ventilator-induced lung injury in mice

Simvastatin decreases hyperbaric oxygen-induced acute lung injury by upregulating enos

Simvastatin decreases lipopolysaccharideinduced pulmonary inflammation in healthy volunteers

COVID-19 and comorbidities: a systematic review and meta-analysis

Risk Factors Associated with Mortality among Patients with COVID-19 in Intensive Care Units in Lombardy, Italy

Relation of Cardiovascular Risk Factors to Mortality and Cardiovascular Events in Hospitalized Patients with Coronavirus Disease

The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses

Methods Commentary: Risk of Bias in Cohort Studies

What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes

Meta-analysis in clinical trials

Review papers: The statistical basis of meta-analysis

Quantifying heterogeneity in a meta-analysis

Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry

Bias in meta-analysis detected by a simple, graphical test

The benefit of statins in SARS-CoV-2 patients: further metabolic and prospective clinical studies are needed

Association between statin use and outcomes in patients 21

Effect of statin therapy on SARS-CoV-2 infection-related mortality in hospitalized patients

Estimating risk of mechanical ventilation and mortality among adult COVID-19 patients admitted to Mass General Brigham: The VICE and DICE scores

Atorvastatin associated with decreased hazard for death in COVID-19 patients admitted to an ICU: a retrospective cohort study

Risk Factors Associated With In-Hospital Mortality in a US National Sample of Patients With COVID-19

Statin Use and In-Hospital Mortality in Patients With Diabetes Mellitus and COVID-19

Statin use is associated with decreased risk of invasive mechanical ventilation in COVID-19 patients: A preliminary study

Role of Drugs Used for Chronic Disease Management on Susceptibility and Severity of COVID-19: A Large Case-Control Study

In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19

Statins as an adjunctive therapy for COVID-19: the clinical plausibility

Modulation of inflammatory mediators and PPARγ and NFκB expression by pravastatin in response to lipoproteins in human monocytes in vitro

ARDS Subphenotypes and Differential Response to Simvastatin: Secondary Analysis of a Randomized Controlled Trial

Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial

Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: An analysis of the PROVE-IT TIMI-22 trial

Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study

Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes

Adherence to Lipid-lowering Therapy and the Use of Preventive Health Services: An Investigation of the Healthy User Effect

Statin use and the risk of cardiovascular implantable electronic device infection: A cohort study in a veteran population

Statin Medication Use and Nosocomial Infection Risk in the Acute Phase of Stroke

Lipid rafts are involved in SARS-CoV entry into Vero E6 cells

Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and Mortality Among COVID-19 Patients: A Systematic Review and Meta-analysis

Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and the Risk of SARS-CoV-2 Infection or Hospitalization With COVID-19 Disease: A Systematic Review and Meta-analysis